
AAPG Stock Forecast & Price Target
AAPG Analyst Ratings
Bulls say
Ascentage Pharma Group is poised for success as it expands globally, with two successful cancer drugs in its portfolio and an extensive pipeline of potential treatments. However, the company's future success is not without risks, including competition from other biotech companies and the potential for delays in drug development.
Bears say
Ascentage Pharma Group is a clinical-stage biotechnology company with a negative outlook due to limited market visibility and commercial validation of their earlier-stage programs, potential regulatory restrictions in China, and potential competition from third-generation TKIs driving market expansion through 2032, leading to a projected peak revenue of $1.3B by 2034. Additionally, concerns around potential dilution from possible manufacturing expansions and commercial launches may also impact the company's financials and future prospects.
This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares